Drug Approval | December 28, 2021
Dr Reddy’s receives Emergency Use Authorisation for molnupiravir
The company will market it under the brand name Molflu
The company will market it under the brand name Molflu
The drug will be marketed under the brand name Molnaflu
SK bioscience secures long-term license to supply the Novavax vaccine for the Korean market
Alzheimer's disease is a serious, progressive and devastating disease with few treatment options
Autism spectrum disorder affects 78 million people and families worldwide
Innovative market development collaboration also signed, expanding the availability of select Novartis oncology products in regions across China currently not covered by Novartis
The NMPA approval is based on the positive data of GEMSTONE-302 study, a multi-center, randomized, double-blind, phase III study that evaluated the efficacy and safety of Cejemly or placebo in combination with chemotherapy in first-line stage IV NSCLC patients
The Indian Council of Medical Research (ICMR), intends to enter into non-exclusive agreements with companies
The surgery was helmed by Prof. Dr. Vishwanath Pai, Sr. Consultant, Department of Minimally Invasive Surgery, Prashanth Hospitals, Velachery
The medicine is the first and only oral MET inhibitor to receive CHMP positive opinion in Europe for adult patients with advanced NSCLC harbouring alterations leading to METex14 skipping
Subscribe To Our Newsletter & Stay Updated
